Simon Rule Selected Research

Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)

1/2021	Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.
1/2021	Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma.
1/2021	Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.
1/2021	The 5-year follow-up of a real-world observational study of patients in the United Kingdom and Ireland receiving ibrutinib for relapsed/refractory mantle cell lymphoma.
1/2021	Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study.
10/2020	What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?
1/2020	Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy.
11/2019	Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma.
9/2019	Molecular signatures for CCN1, p21 and p27 in progressive mantle cell lymphoma.
1/2019	Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Simon Rule Research Topics

Disease

42	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2021 - 10/2010
13	Neoplasms (Cancer) 11/2021 - 06/2004
10	Disease Progression 12/2020 - 08/2011
8	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 12/2020 - 06/2015
7	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2022 - 12/2011
7	Lymphoma (Lymphomas) 12/2017 - 10/2010
5	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 10/2021 - 07/2007
5	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2020 - 11/2010
5	Neutropenia 08/2017 - 08/2011
4	Hemorrhage 12/2020 - 07/2007
4	Thrombocytopenia (Thrombopenia) 08/2017 - 08/2011
3	Waldenstrom Macroglobulinemia (Macroglobulinemia) 12/2020 - 01/2013
3	Nausea 10/2019 - 08/2011
3	Fatigue 10/2019 - 11/2017
3	Infections 03/2016 - 08/2011
2	Edema (Dropsy) 01/2021 - 11/2017
2	Atrial Fibrillation 12/2020 - 10/2017
2	Vomiting 10/2019 - 08/2011
2	B-Cell Lymphoma (Lymphoma, B Cell) 01/2018 - 11/2017
2	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 06/2015 - 06/2015
2	Genetic Translocation (Chromosomal Translocation) 04/2015 - 12/2011
2	Hodgkin Disease (Hodgkin's Disease) 01/2012 - 05/2010
2	Multiple Myeloma 12/2011 - 12/2008
2	Rheumatoid Arthritis 03/2004 - 09/2002
1	Residual Neoplasm 01/2021
1	Hypertension (High Blood Pressure) 12/2020
1	COVID-19 01/2020
1	Mucositis 10/2019
1	Dyspepsia (Indigestion) 10/2019
1	Chronic Disease (Chronic Diseases) 11/2018
1	Carcinogenesis 01/2018
1	Cough 11/2017
1	Dizziness (Lightheadedness) 11/2017
1	Dyspnea (Shortness of Breath) 11/2017
1	Hematologic Neoplasms (Hematological Malignancy) 10/2017
1	Leukopenia 08/2017
1	Anemia 08/2017
1	Bone Diseases (Bone Disease) 01/2017
1	Diarrhea 08/2015
1	Lymphocytosis 07/2015
1	Second Primary Neoplasms (Neoplasms, Second) 01/2013

Drug/Important Bio-Agent (IBA)

25	ibrutinibIBA 01/2021 - 08/2013
19	Rituximab (Mabthera)FDA Link 01/2022 - 11/2010
15	Agammaglobulinaemia Tyrosine KinaseIBA 11/2021 - 08/2013
10	Bortezomib (Velcade)FDA Link 11/2018 - 12/2008
6	acalabrutinibIBA 11/2021 - 01/2018
6	Bendamustine Hydrochloride FDA Link 12/2020 - 02/2016
6	Lenalidomide (CC 5013)FDA Link 01/2018 - 03/2016
5	fludarabineIBA 01/2020 - 01/2013
5	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2020 - 01/2015
3	Cyclin D1IBA 09/2019 - 12/2011
3	temsirolimus FDA Link 12/2017 - 02/2016
3	Monoclonal AntibodiesIBA 10/2017 - 01/2012
2	zanubrutinibIBA 01/2021 - 12/2020
2	obinutuzumabIBA 01/2021 - 01/2017
2	Dexamethasone (Maxidex)FDA LinkGeneric 01/2020 - 12/2011
2	Prednisolone (Predate)FDA LinkGeneric 01/2020 - 01/2015
2	Chlorambucil (Leukeran)FDA Link 01/2020 - 01/2013
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2020 - 01/2015
2	Pharmaceutical PreparationsIBA 01/2020 - 03/2016
2	Vincristine (Oncovin)FDA LinkGeneric 01/2020 - 01/2015
2	Cytarabine (Cytosar-U)FDA LinkGeneric 12/2018 - 10/2013
1	OligonucleotidesIBA 01/2021
1	venetoclaxIBA 01/2021
1	Enoxaparin (Lovenox)FDA LinkGeneric 12/2020
1	Antipsychotic Agents (Antipsychotics)IBA 01/2020
1	Tricyclic Antidepressive Agents (Tricyclic Antidepressants)IBA 01/2020
1	Antimalarials (Antimalarial Agents)IBA 01/2020
1	Mitoxantrone (Novantrone)FDA LinkGeneric 01/2020
1	QuinolonesIBA 01/2020
1	Selective Estrogen Receptor Modulators (SERM)IBA 01/2020
1	Mechanistic Target of Rapamycin Complex 1IBA 10/2019
1	vistusertibIBA 10/2019
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 09/2019
1	Protein Isoforms (Isoforms)IBA 09/2019
1	AnticoagulantsIBA 01/2019
1	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2018
1	InterferonsIBA 01/2018
1	olaparibIBA 01/2018
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2018
1	CD20 AntigensIBA 10/2017
1	Gemcitabine FDA Link 08/2017
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 08/2017
1	Etoposide (VP 16)FDA LinkGeneric 08/2017
1	Antineoplastic Agents (Antineoplastics)IBA 03/2016
1	ofatumumab FDA Link 05/2014
1	Biomarkers (Surrogate Marker)IBA 05/2013
1	purineIBA 01/2013
1	Alkylating AgentsIBA 01/2013
1	Brentuximab VedotinIBA 01/2012
1	Rifampin (Rifampicin)FDA LinkGeneric 12/2011
1	Proteasome Endopeptidase Complex (Proteasome)IBA 12/2011
1	Cytochrome P-450 CYP3AIBA 12/2011

Therapy/Procedure

25	Therapeutics 11/2021 - 07/2007
10	Drug Therapy (Chemotherapy) 12/2018 - 01/2012
8	Stem Cell Transplantation 10/2019 - 09/2002
2	Transplantation 10/2010 - 03/2004
1	Induction Chemotherapy 01/2022
1	Molecular Targeted Therapy 06/2017
1	Intravenous Infusions 08/2011